亚洲国家炎症性肠病患者的治疗模式发生了怎样的变化?

IF 3.4 Q2 GASTROENTEROLOGY & HEPATOLOGY
Jihye Park
{"title":"亚洲国家炎症性肠病患者的治疗模式发生了怎样的变化?","authors":"Jihye Park","doi":"10.5217/ir.2023.00061","DOIUrl":null,"url":null,"abstract":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 275 gy of IBD, according to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study, from 1990 to 2019, age-standardized prevalence increased most rapidly in East Asia and high-income Asia-Pacific regions. According to the healthcare costs, van Linschoten et al. assessed the cost of illness of IBD according to each continent including Asia, Europe, North America, and Oceania from 1985 to 2018. The healthcare costs were increasing on all continents, and the cost trend is primarily attributable to an increase in medication costs. Although costs in Asia were lower than in Europe and North America, but no studies from Asia or Oceania were eligible for this analysis at that time period. In summary, it is essential to understand treatment patterns for IBD in Asian countries, because of rapid increase of IBD in Asia due to Westernization, changes in prescription patterns in the West over time, and unique characteristics between the East and the West. The organizing committee of the Asian Organization for Crohn’s and Colitis (AOCC) reported first web-based survey results for the current status of IBD management conducted by 353 Asian medical doctors from Korea, China, Japan, India, Hon Kong, Singapore, Taiwan, Malaysia, Philippines, and Indonesia in the 2nd annual AOCC meeting in 2014. For mild to moderate UC and mild to moderate Crohn’s disease (CD), 5-aminosalicylic acid treatment were common first line therapy in Asian countries. For steroid-refractory acute severe UC, most physicians selected anti-tumor necrosis factor (TNF) agents followed by cyclosporine, on the contrary, Japanese pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00061 Intest Res 2023;21(3):275-276","PeriodicalId":14481,"journal":{"name":"Intestinal Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/67/ir-2023-00061.PMC10397554.pdf","citationCount":"0","resultStr":"{\"title\":\"How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?\",\"authors\":\"Jihye Park\",\"doi\":\"10.5217/ir.2023.00061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 275 gy of IBD, according to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study, from 1990 to 2019, age-standardized prevalence increased most rapidly in East Asia and high-income Asia-Pacific regions. According to the healthcare costs, van Linschoten et al. assessed the cost of illness of IBD according to each continent including Asia, Europe, North America, and Oceania from 1985 to 2018. The healthcare costs were increasing on all continents, and the cost trend is primarily attributable to an increase in medication costs. Although costs in Asia were lower than in Europe and North America, but no studies from Asia or Oceania were eligible for this analysis at that time period. In summary, it is essential to understand treatment patterns for IBD in Asian countries, because of rapid increase of IBD in Asia due to Westernization, changes in prescription patterns in the West over time, and unique characteristics between the East and the West. The organizing committee of the Asian Organization for Crohn’s and Colitis (AOCC) reported first web-based survey results for the current status of IBD management conducted by 353 Asian medical doctors from Korea, China, Japan, India, Hon Kong, Singapore, Taiwan, Malaysia, Philippines, and Indonesia in the 2nd annual AOCC meeting in 2014. For mild to moderate UC and mild to moderate Crohn’s disease (CD), 5-aminosalicylic acid treatment were common first line therapy in Asian countries. For steroid-refractory acute severe UC, most physicians selected anti-tumor necrosis factor (TNF) agents followed by cyclosporine, on the contrary, Japanese pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00061 Intest Res 2023;21(3):275-276\",\"PeriodicalId\":14481,\"journal\":{\"name\":\"Intestinal Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/67/ir-2023-00061.PMC10397554.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intestinal Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5217/ir.2023.00061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intestinal Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5217/ir.2023.00061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 275 gy of IBD, according to the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study, from 1990 to 2019, age-standardized prevalence increased most rapidly in East Asia and high-income Asia-Pacific regions. According to the healthcare costs, van Linschoten et al. assessed the cost of illness of IBD according to each continent including Asia, Europe, North America, and Oceania from 1985 to 2018. The healthcare costs were increasing on all continents, and the cost trend is primarily attributable to an increase in medication costs. Although costs in Asia were lower than in Europe and North America, but no studies from Asia or Oceania were eligible for this analysis at that time period. In summary, it is essential to understand treatment patterns for IBD in Asian countries, because of rapid increase of IBD in Asia due to Westernization, changes in prescription patterns in the West over time, and unique characteristics between the East and the West. The organizing committee of the Asian Organization for Crohn’s and Colitis (AOCC) reported first web-based survey results for the current status of IBD management conducted by 353 Asian medical doctors from Korea, China, Japan, India, Hon Kong, Singapore, Taiwan, Malaysia, Philippines, and Indonesia in the 2nd annual AOCC meeting in 2014. For mild to moderate UC and mild to moderate Crohn’s disease (CD), 5-aminosalicylic acid treatment were common first line therapy in Asian countries. For steroid-refractory acute severe UC, most physicians selected anti-tumor necrosis factor (TNF) agents followed by cyclosporine, on the contrary, Japanese pISSN 1598-9100 • eISSN 2288-1956 https://doi.org/10.5217/ir.2023.00061 Intest Res 2023;21(3):275-276
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Intestinal Research
Intestinal Research GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
7.40
自引率
10.20%
发文量
69
审稿时长
38 weeks
期刊介绍: Intestinal Research (Intest Res) is the joint official publication of the Asian Organization for Crohn''s and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn''s Foundation (India) (CCF, india). The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance. As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines. The Journal also seeks to propagate and exchange useful innovations, both in ideas and in practice, within the research community. As a mode of scholarly communication, it encourages scientific investigation through the rigorous peer-review system and constitutes a qualified and continual platform for sharing studies of researchers and practitioners. Specifically, the Journal presents up-to-date coverage of medical researches on the physiology, epidemiology, pathophysiology, clinical presentations, and therapeutic interventions of the intestinal diseases. General topics of interest include inflammatory bowel disease, colon and small intestine cancer or polyp, endoscopy, irritable bowel syndrome and other motility disorders, infectious enterocolitis, intestinal tuberculosis, and so forth. The Journal publishes diverse types of academic materials such as editorials, clinical and basic reviews, original articles, case reports, letters to the editor, brief communications, perspective, statement or commentary, and images that are useful to clinicians and researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信